Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
ROCKVILLE, MD, Jan. 04, 2018 --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 11, 2018 at 11:00 a.m. PT (2:00 p.m. ET).
A webcast of MacroGenics' presentation may be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc.
###
CONTACTS: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected] Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, [email protected]
